James MacKaness - Soleno Therapeutics Chief Officer
| SLNO Stock | USD 58.34 1.12 1.96% |
Insider
James MacKaness is Chief Officer of Soleno Therapeutics
| Age | 60 |
| Address | 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065 |
| Phone | 650 213 8444 |
| Web | https://soleno.life |
Soleno Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4805) % which means that it has lost $0.4805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9111) %, meaning that it created substantial loss on money invested by shareholders. Soleno Therapeutics' management efficiency ratios could be used to measure how well Soleno Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Soleno Therapeutics' Total Assets are very stable compared to the past year. As of the 27th of November 2024, Non Current Assets Total is likely to grow to about 9.9 M, while Non Currrent Assets Other are likely to drop about 141.1 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| MBA CMA | Pulmatrix | 69 | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Waldemar Priebe | Moleculin Biotech | N/A | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Catherine Kelleher | Capricor Therapeutics | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Donald Picker | Moleculin Biotech | 78 | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| Randall Schatzman | Bolt Biotherapeutics | 69 | |
| Xavier Avat | Capricor Therapeutics | N/A | |
| Torsten Hombeck | Akari Therapeutics PLC | 54 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Mirella Toro | Annexon | N/A | |
| FACP MD | Moleculin Biotech | 70 | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Peter MBA | Bio Path Holdings | 75 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| MBA MBA | Inozyme Pharma | 65 | |
Management Performance
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.48 |
Soleno Therapeutics Leadership Team
Elected by the shareholders, the Soleno Therapeutics' board of directors comprises two types of representatives: Soleno Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Soleno. The board's role is to monitor Soleno Therapeutics' management team and ensure that shareholders' interests are well served. Soleno Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Soleno Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kristen MS, Senior Operations | ||
| Dr MBA, Senior Development | ||
| Patricia MPH, Senior Affairs | ||
| PharmD MBA, Senior Affairs | ||
| Meredith MBA, Chief Officer | ||
| Anish MD, CEO and President | ||
| Jesse Schumaker, General Counsel | ||
| Anthony Wondka, Vice President - Research and Development | ||
| James MacKaness, Chief Officer | ||
| Lauren Budesheim, Vice People | ||
| Michael MD, Senior Development | ||
| Patricia Hirano, Vice Affairs |
Soleno Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Soleno Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 2.26 B | ||||
| Shares Outstanding | 43.12 M | ||||
| Shares Owned By Insiders | 3.04 % | ||||
| Shares Owned By Institutions | 96.96 % | ||||
| Number Of Shares Shorted | 6.17 M | ||||
| Price To Earning | (3.71) X | ||||
| Price To Book | 9.50 X | ||||
| EBITDA | (37.03 M) |
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Soleno Stock
| 0.71 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Soleno Stock
| 0.71 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.68 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.66 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.65 | PEPG | PepGen | PairCorr |
| 0.53 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.